Form 4: Adverum Biotechnologies Director James Scopa Granted 10,450 Stock Options

Adverum Biotechnologies, Inc. Director James Paul Scopa was granted 10,450 stock options with an exercise price of $2.32, vesting on June 17, 2026, or the 2026 annual meeting.

Summary

• James Paul Scopa, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The transaction date for this grant was June 17, 2025.
• The exercise price for these stock options is $2.32 per share.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is subject to Mr. Scopa's continued service with Adverum Biotechnologies, Inc. on the vesting date.
• Accelerated vesting will occur upon a change of control of the Issuer.
• The expiration date for these stock options is June 16, 2035.
• Following this transaction, Mr. Scopa beneficially owns 10,450 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard compensation practice that aligns director interests with shareholders. It is a routine transaction and not indicative of significant positive or negative operational news.

Positives

• The grant of stock options aligns the financial interests of Director James Paul Scopa with those of Adverum Biotechnologies' shareholders, incentivizing long-term performance.
• This is a standard form of compensation for directors, reflecting ongoing commitment and service to the company.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, although this is a common aspect of equity-based compensation plans.

Future Outlook

The stock options granted to Director Scopa are set to vest on June 17, 2026, or at the 2026 annual meeting of stockholders, whichever comes first, contingent on his continued service. The options have a long-term expiration date of June 16, 2035, providing a significant window for potential exercise.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and broader corporate sectors. It serves as a key component of executive and director compensation, aiming to align the interests of leadership with long-term shareholder value creation. This particular grant is consistent with typical compensation structures for non-employee directors in publicly traded companies.

Related Party Transactions

• The grant of 10,450 stock options to James Paul Scopa, a Director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (James Paul Scopa): Receives equity-based compensation, providing an incentive tied to the company's stock performance and continued service.

Next Steps

• The stock options will vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service.
• Director Scopa may exercise the vested options at any time before the expiration date of June 16, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Compensation, Corporate Governance